Cudetaxestat for IPF Found Safe in Phase 1 Trial of Healthy Volunteers

Cudetaxestat for IPF Found Safe in Phase 1 Trial of Healthy Volunteers

313323

Cudetaxestat for IPF Found Safe in Phase 1 Trial of Healthy Volunteers

Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly is overactive in people with IPF and other fibrotic disorders. Blocking autotaxin activity and the release of pro-fibrotic signals is expected to reduce tissue scarring in these…

You must be logged in to read/download the full post.